{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:35:04Z","timestamp":1789608904424,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"am","delay-in-days":281,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.idnow.2023.104807","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:01:03Z","timestamp":1697198463000},"page":"104807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"54","author":[{"given":"Thomas","family":"Maitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Baulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-4793","authenticated-orcid":false,"given":"Alexandra","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5660-6544","authenticated-orcid":false,"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2023.104807_b0005","doi-asserted-by":"crossref","unstructured":"Streptomycin treatment of pulmonary tuberculosis: a medical research council investigation. BMJ 1948;2(4582):769\u201382.","DOI":"10.1136\/bmj.2.4582.769"},{"key":"10.1016\/j.idnow.2023.104807_b0010","unstructured":"WHO (World Health Organization). Global tuberculosis report 2020. 2020;53(9):1689\u201399. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports (06\/10\/2023)."},{"key":"10.1016\/j.idnow.2023.104807_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jama.300.18.2153","article-title":"Extensively drug-resistant tuberculosis in the United States, 1993\u20132007","author":"Shah","year":"2008","journal-title":"J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.idnow.2023.104807_b0020","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/00006454-199510000-00013","article-title":"Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease","volume":"14","author":"Friedland","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idnow.2023.104807_b0025","unstructured":"Gunnar Kahlmeter and the EUCAST Steering Committee. Redefining susceptibility testing categories S, I and R. https:\/\/fr.scribd.com\/document\/495820325\/EUCAST-Intermediate-category-information-for-all 06\/10\/2023."},{"key":"10.1016\/j.idnow.2023.104807_b0030","doi-asserted-by":"crossref","unstructured":"Group AST, Georghiou SB, Rodwell TC, Korobitsyn A, Abbadi SH, Ajbani K, et al. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal [Internet]. 1 avr 2022 [cit\u00e9 8 f\u00e9vr 2023];59(4). Disponible sur: http:\/\/erj.ersjournals.com\/content\/59\/4\/2200166.","DOI":"10.1183\/13993003.00166-2022"},{"issue":"4","key":"10.1016\/j.idnow.2023.104807_b0035","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/jac\/dkp262","article-title":"Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis","volume":"64","author":"Sch\u00f6n","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2023.104807_b0040","doi-asserted-by":"crossref","unstructured":"Ghodousi A, Tagliani E, Karunaratne E, Niemann S, Perera J, K\u00f6ser CU, et al. Isoniazid resistance in mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping MIC distributions with different underlying resistance mechanisms. Antimicrobial agents and chemotherapy [Internet]. 1 juill 2019 [cit\u00e9 13 ao\u00fbt 2020];63(7). Disponible sur: https:\/\/aac-asm-org.proxy.insermbiblio.inist.fr\/content\/63\/7\/e00092-19.","DOI":"10.1128\/AAC.00092-19"},{"issue":"11","key":"10.1016\/j.idnow.2023.104807_b0045","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.clinthera.2020.09.009","article-title":"A systematic review and meta-analysis of isoniazid pharmacokinetics in healthy volunteers and patients with tuberculosis","volume":"42","author":"Hong","year":"2020","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.idnow.2023.104807_b0050","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1128\/AAC.43.12.2922","article-title":"High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother d\u00e9c"},{"issue":"11","key":"10.1016\/j.idnow.2023.104807_b0055","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1128\/AAC.37.11.2344","article-title":"Therapy of multidrug-resistant tuberculosis: lessons from studies with mice","volume":"37","author":"Klemens","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idnow.2023.104807_b0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmi.2014.08.008","article-title":"Treatment outcome of patients with isoniazid mono-resistant tuberculosis","volume":"21","author":"Chien","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.idnow.2023.104807_b0065","doi-asserted-by":"crossref","first-page":"e0141002","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PLOS ONE"},{"issue":"9","key":"10.1016\/j.idnow.2023.104807_b0070","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/AAC.00462-15","article-title":"Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs","volume":"59","author":"Lalande","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idnow.2023.104807_b0075","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis","volume":"12","author":"Katiyar","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.idnow.2023.104807_b0080","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.idnow.2023.104807_b0085","doi-asserted-by":"crossref","first-page":"e1002591","DOI":"10.1371\/journal.pmed.1002591","article-title":"Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis","volume":"15","author":"Harausz","year":"2018","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.idnow.2023.104807_b0090","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/cid\/ciz039","article-title":"Improved outcomes with high-dose isoniazid in multidrug-resistant tuberculosis treatment in Haiti","volume":"69","author":"Walsh","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idnow.2023.104807_b0095","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S1473-3099(18)30073-2","article-title":"Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study","volume":"18","author":"Zignol","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.idnow.2023.104807_b0100","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1164\/rccm.201910-1960OC","article-title":"Early bactericidal activity of different isoniazid doses for drug-resistant tuberculosis (INHindsight): a randomized, open-label clinical trial","volume":"201","author":"Dooley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.idnow.2023.104807_b0105","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1016\/S2666-5247(22)00116-1","article-title":"Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study","volume":"3","author":"Finci","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.idnow.2023.104807_b0110","article-title":"Early bactericidal activity of different isoniazid doses for drug resistant TB (INHindsight): a randomized open-label clinical trial","volume":"16","author":"Dooley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.idnow.2023.104807_b0115","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1164\/rccm.202103-0534OC","article-title":"A semimechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis: results from a randomized clinical trial","volume":"204","author":"Gausi","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.idnow.2023.104807_b0120","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jama.1981.03320100038026","article-title":"Single high-dose pyridoxine treatment for isoniazid overdose","volume":"246","author":"Wason","year":"1981","journal-title":"J Am Med Assoc"},{"issue":"11","key":"10.1016\/j.idnow.2023.104807_b0125","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1469-0691.2010.03267.x","article-title":"Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray","volume":"16","author":"Yao","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idnow.2023.104807_b0130","unstructured":"World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva, Switzerland. 2021; https:\/\/www.who.int\/publications\/i\/item\/9789240017283 26\/10\/2023."},{"issue":"9","key":"10.1016\/j.idnow.2023.104807_b0135","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.idnow.2023.104807_b0140","doi-asserted-by":"crossref","unstructured":"Al-Mutairi NM, Ahmad S, Mokaddas E, Eldeen HS, Joseph S. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. BMC Infect Dis [Internet]. 3 janv 2019 [cit\u00e9 11 ao\u00fbt 2020];19. Disponible sur: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6318973\/.","DOI":"10.1186\/s12879-018-3638-z"},{"issue":"8","key":"10.1016\/j.idnow.2023.104807_b0145","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JCM.00553-13","article-title":"Rifampin drug resistance tests for tuberculosis: challenging the gold standard","volume":"51","author":"Deun","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idnow.2023.104807_b0150","doi-asserted-by":"crossref","first-page":"2100783","DOI":"10.1183\/13993003.00783-2021","article-title":"Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown","author":"Van Deun","year":"2021","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.idnow.2023.104807_b0155","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2169\/internalmedicine.9571-17","article-title":"Successful treatment with a high-dose rifampin-containing regimen for pulmonary tuberculosis with a disputed rpoB mutation","volume":"57","author":"Jeong","year":"2018","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.idnow.2023.104807_b0160","doi-asserted-by":"crossref","first-page":"990","DOI":"10.5588\/ijtld.10.0127","article-title":"Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge","volume":"15","author":"van Ingen","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.idnow.2023.104807_b0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idnow.2023.104807_b0170","unstructured":"Brake LHM te, Jager V de, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, et al. Increased bactericidal activity but dose-limiting intolerability at 50 mg\u00b7kg\u22121 rifampicin. European Respiratory Journal [Internet]. 1 janv 2021 [cit\u00e9 15 mars 2021]; Disponible sur: http:\/\/erj.ersjournals.com\/content\/early\/2020\/12\/10\/13993003.00955-2020."},{"issue":"9","key":"10.1016\/j.idnow.2023.104807_b0175","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/AAC.00393-16","article-title":"Wild-type and non-wild-type mycobacterium tuberculosis MIC distributions for the novel fluoroquinolone antofloxacin compared with those for ofloxacin, levofloxacin, and moxifloxacin","volume":"60","author":"Yu","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idnow.2023.104807_b0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","article-title":"Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of mycobacterium tuberculosis: functional analysis of mutant enzymes","volume":"50","author":"Aubry","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idnow.2023.104807_b0185","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.idnow.2023.104807_b0190","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idnow.2023.104807_b0195","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.01478-13","article-title":"Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients","volume":"58","author":"Zvada","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idnow.2023.104807_b0200","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02107-2018","article-title":"Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients","volume":"53","author":"Ghimire","year":"2019","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.idnow.2023.104807_b0205","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkw164","article-title":"Pharmacokinetic\/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB","volume":"71","author":"Ghimire","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.idnow.2023.104807_b0210","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00770-18","article-title":"Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2023.104807_b0215","doi-asserted-by":"crossref","unstructured":"Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, et al. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic\/Pharmacodynamic Target Attainment To Guide Dose Selection. Antimicrobial Agents and Chemotherapy [Internet]. 1 juill 2019 [cit\u00e9 19 ao\u00fbt 2020];63(7). Disponible sur: https:\/\/aac-asm-org.proxy.insermbiblio.inist.fr\/content\/63\/7\/e00279-19.","DOI":"10.1128\/AAC.00279-19"},{"issue":"11","key":"10.1016\/j.idnow.2023.104807_b0220","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1128\/AAC.00968-10","article-title":"Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model","volume":"54","author":"Poissy","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idnow.2023.104807_b0225","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1128\/AAC.00506-13","article-title":"Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis","volume":"57","author":"Fillion","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idnow.2023.104807_b0230","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02516-18","article-title":"Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations","volume":"63","author":"Sarathy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idnow.2023.104807_b0235","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u00ab 9-month Bangladesh regimen \u00bb for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.idnow.2023.104807_b0240","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/jac\/dkv360","article-title":"Specific gyrA gene mutations predict poor treatment outcome in MDR-TB","volume":"71","author":"Rigouts","year":"2016","journal-title":"J Antimicrob Chemother f\u00e9vr"},{"issue":"8","key":"10.1016\/j.idnow.2023.104807_b0245","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1128\/AAC.00425-16","article-title":"Moxifloxacin improves treatment outcomes in patients with ofloxacin-resistant multidrug-resistant tuberculosis","volume":"60","author":"Chien","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"10.1016\/j.idnow.2023.104807_b0250","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/acschembio.0c00184","article-title":"Structure-guided optimization of inhibitors of acetyltransferase Eis from Mycobacterium tuberculosis","volume":"15","author":"Punetha","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.idnow.2023.104807_b0255","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, Switzerland. 2019; https:\/\/www.who.int\/publications-detail-redirect\/9789240063129 06\/10\/2023."},{"issue":"5144","key":"10.1016\/j.idnow.2023.104807_b0260","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1994","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.idnow.2023.104807_b0265","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3390\/microorganisms10071436","article-title":"How a PCR sequencing strategy can bring new data to improve the diagnosis of ethionamide resistance","volume":"10","author":"Maitre","year":"2022","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.idnow.2023.104807_b0270","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1128\/AAC.01030-10","article-title":"Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis","volume":"55","author":"Brossier","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idnow.2023.104807_b0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2958.2003.03809.x","article-title":"EthR, a repressor of the TetR\/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator","volume":"51","author":"Engohang-Ndong","year":"2004","journal-title":"Mol Microbiol"},{"issue":"6330","key":"10.1016\/j.idnow.2023.104807_b0280","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1126\/science.aag1006","article-title":"Reversion of antibiotic resistance inMycobacterium tuberculosisby spiroisoxazoline SMARt-420","volume":"355","author":"Blondiaux","year":"2017","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.idnow.2023.104807_b0285","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nm.1950","article-title":"Synthetic EthR inhibitors boost antituberculous activity of ethionamide","volume":"15","author":"Willand","year":"2009","journal-title":"Nature Med"},{"issue":"9","key":"10.1016\/j.idnow.2023.104807_b0290","first-page":"983","article-title":"Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Review of Anti-infective","volume":"10","author":"Viveiros","year":"2012","journal-title":"Therapy"},{"issue":"4","key":"10.1016\/j.idnow.2023.104807_b0295","doi-asserted-by":"crossref","first-page":"e34538","DOI":"10.1371\/journal.pone.0034538","article-title":"Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis","volume":"7","author":"Machado","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.idnow.2023.104807_b0300","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/651377","article-title":"Efflux-pump\u2013derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol","volume":"201","author":"Srivastava","year":"2010","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.idnow.2023.104807_b0305","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00284-012-0215-3","article-title":"The Expression of ABC Efflux Pump, Rv1217c\u2013Rv1218c, and its association with multidrug resistance of Mycobacterium tuberculosis in China","volume":"66","author":"Wang","year":"2013","journal-title":"Curr Microbiol"},{"issue":"8","key":"10.1016\/j.idnow.2023.104807_b0310","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1128\/AAC.48.8.3175-3178.2004","article-title":"Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis","volume":"48","author":"Pasca","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idnow.2023.104807_b0315","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00232-017-9982-x","article-title":"Mycobacterium tuberculosis major facilitator superfamily transporters","volume":"250","author":"Li","year":"2017","journal-title":"J Membrane Biol"},{"issue":"5","key":"10.1016\/j.idnow.2023.104807_b0320","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idnow.2023.104807_b0325","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1128\/IAI.73.6.3492-3501.2005","article-title":"Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance","volume":"73","author":"Domenech","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.idnow.2023.104807_b0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jgar.2019.01.003","article-title":"Expression analysis of 10 efflux pump genes in multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis clinical isolates","volume":"17","author":"Kardan-Yamchi","year":"2019","journal-title":"J Global Antimicrobial Resistance"},{"issue":"7","key":"10.1016\/j.idnow.2023.104807_b0335","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bcp.2005.12.008","article-title":"Practical applications and feasibility of efflux pump inhibitors in the clinic\u2014A vision for applied use","volume":"71","author":"Lomovskaya","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.idnow.2023.104807_b0340","doi-asserted-by":"crossref","unstructured":"Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K, et al. Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. Antimicrob Agents Chemother [Internet]. janv 2018 [cit\u00e9 29 juill 2021];62(1). Disponible sur: https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01692-17.","DOI":"10.1128\/AAC.01692-17"},{"issue":"6","key":"10.1016\/j.idnow.2023.104807_b0345","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1365-2958.2005.04510.x","article-title":"The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol","volume":"55","author":"Colangeli","year":"2005","journal-title":"Mol Microbiol"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991923001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991923001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:33:58Z","timestamp":1763019238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991923001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666991923001690"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2023.104807","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2023.104807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104807"}}